InterCure Ltd. — Form 6-K Summary
Business context and reporting period
InterCure Ltd., an Israeli foreign private issuer, filed Form 6-K on May 16, 2023, covering the month of May 2023. The filing includes management’s discussion and analysis and unaudited interim condensed consolidated financial statements for the three-month periods ended March 31, 2023 and March 31, 2022.
Financial metrics
The provided filing text is limited to the Form 6-K cover page and does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics. These details are included in Exhibits 99.2 and 99.3 but were not provided in the source text.
Material changes versus the prior comparable period
The filing identifies a comparison between the three months ended March 31, 2023 and March 31, 2022. The provided text does not disclose the amounts or nature of material period-over-period changes.
Guidance, outlook, risks, and unusual items
The provided text does not include guidance, outlook commentary, risk disclosures, contingencies, or unusual items. Such information may be addressed in the attached press release or management’s discussion and analysis.
Exhibits and investor verification items
- Exhibit 99.1: Press release dated May 15, 2023.
- Exhibit 99.2: Management’s Discussion and Analysis for the three-month periods ended March 31, 2023 and 2022.
- Exhibit 99.3: Unaudited interim condensed consolidated financial statements for the period ended March 31, 2023.
- Verify the reported revenue, profitability, operating cash flow, cash balance, debt, liquidity, and margins in Exhibits 99.2 and 99.3.
- Review the press release and MD&A for management commentary, guidance, risks, contingencies, and significant unusual items.